Answers are grounded in this paper and cite their sources.
Comprehensive genomic profiling improves therapeutic selection in ultra-rare sarcomas, suggesting better patient outcomes.
Conclusions: Comprehensive genomic profiling improved diagnostic precision and revealed rare, oncogenically meaningful, and potentially targetable events.These findings highlight the role of NGS in guiding risk stratification, therapeutic selection, and clinical-trial matching in ultra-rare sarcomas.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: